A Half-Billion-Dollar Bet on Silencing Genes
ADARx Pharmaceuticals just raised $446 million in an upsized IPO, with AbbVie kicking in another $100 million on the side. It's one of the largest biotech debuts of 2026, and it says a lot about where investor appetite is heading.
Wall Street Just Wrote a Very Large Check
Most biotech startups spend years begging investors to believe in their science. ADARx Pharmaceuticals skipped that phase entirely.
The San Diego-based RNA therapeutics company priced its IPO on September 24 at $17 per share, selling 26.25 million shares for gross proceeds of roughly $446.3 million. That's not a typo. And it's not the whole story: AbbVie, one of the world's largest pharma companies, simultaneously agreed to buy shares in a private placement worth up to $100 million, bringing the total haul to about $535 million before fees.
For a company founded less than seven years ago, that's like showing up to your first day of college with a trust fund and a job offer already in hand.
The Deal Got Bigger, Not Smaller
The most telling detail isn't the final number. It's the trajectory.
ADARx originally filed to sell around 21.9 million shares at $15 to $17 each, targeting roughly $350 million. By pricing day, the company had upsized the offering and priced at the top of the range. In IPO-speak, that's the market's way of saying "we want more." Underwriters including J.P. Morgan, Morgan Stanley, TD Cowen, and UBS still have a 30-day option to buy an additional 3.9 million shares, which would push proceeds even higher.
The stock will trade on the Nasdaq Global Select Market under the ticker ADRX, and closing is expected September 28.
So What Does ADARx Actually Do?
At its core, ADARx develops siRNA therapeutics, which stands for small interfering RNA. Think of it this way: if your DNA is the blueprint for building proteins, RNA is the messenger that carries instructions from that blueprint to the construction crew. siRNA drugs intercept those messengers and silence them, essentially telling your body to stop making a specific protein that's causing disease.
It's like finding the one person in the office who keeps sending terrible company-wide emails and revoking their access. The problem doesn't get fixed after the fact; it never happens in the first place.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
